

Cancer Drug Pipeline Tracking Update

As of March 31, 2017

Objectives of Update

- Review oncology drugs in the pipeline being tracked ending March 31, 2017
- Allocation of 2017 Manufacturers' Survey Results
- Identify key trends

Purpose of Tracking


The pCODR Pipeline Tracker systematically identifies and monitors novel oncology drugs and new indications for pre-existing oncology drugs for the purposes of:

- Gaining awareness of emerging trends in oncology treatment
- Assisting provincial drug programs, cancer agencies and pCODR with proactive health system planning, resource allocation, and possibly prioritization for implementation.


Manufacturers' Survey Results

2013-2014	2015	2016	2017
18 Manufacturers	14 Manufacturers	18 Manufacturers	16 Manufacturers
71 Distinct Drugs <ul style="list-style-type: none"> ▪ 62 New Drugs ▪ 29 New Indications for Existing Drugs 	94 Distinct Drugs <ul style="list-style-type: none"> ▪ 67 New Drugs ▪ 27 New Indications for Existing Drugs 	108 Distinct Drugs <ul style="list-style-type: none"> ▪ 70 New Drugs ▪ 38 New Indications for Existing Drugs 	93 Distinct Drugs <ul style="list-style-type: none"> ▪ 62 New Drugs ▪ 31 New Indications for Existing Drugs
197 Drug-Indication Pairs <ul style="list-style-type: none"> ▪ 119 New Drugs ▪ 78 New Indications for Existing Drugs 	235 Drug-Indication Pairs <ul style="list-style-type: none"> ▪ 176 New Drugs ▪ 59 New Indications for Existing Drugs 	313 Drug-Indication Pairs <ul style="list-style-type: none"> ▪ 198 New Drugs ▪ 115 New Indications for Existing Drugs 	277 Drug-Indication Pairs <ul style="list-style-type: none"> ▪ 148 New Drugs ▪ 122 New Indications for Existing Drugs ▪ 4 radio-pharmaceutical ▪ 3 biosimilar products


Distribution by Route of Administration




Distribution by Trial Status



Distribution by Tumour Site



Distribution by Companion Diagnostic Tests



Some Factors Influencing Submissions to pCODR

Not all drugs and indications undergoing trials will result in a submission to pCODR

- Manufacturer decides not to seek regulatory approval in Canada
Health Canada does not issue NOC
- Manufacturer decides not to submit for national funding review
- Manufacturer decides to submit on interim results of phase 3 trial
- Manufacturer decides to submit with phase 2 data
- Trial fails to meet primary endpoints or halted due to serious adverse events